{"prompt": "['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', 'Table 10:', 'Recommended Dose Modifications for Irinotecan Monotherapy', 'Worst Toxicity, NCI', 'During a Cycle of Therapy', 'At Start of Next Cycle of Therapy', 'Gradeb', '(after adequate recovery),', 'Compared with the Starting Dose', 'of the Previous Cycle', 'Neutropenia', '1 (1500 - 1999/mm\u00b3)', 'Maintain dose level', 'Maintain dose level', '2 (1000 - 1499/mm\u00b3)', '1 25 mg/m\u00b2', 'Maintain dose level', '3 (500 - 999/mm\u00b3)', 'Omit dose level until resolved to VI grade 2, then', '1 25 mg/m\u00b2', '1 25 mg/m\u00b2', '4 (<500/mm\u00b3)', 'Omit dose level until resolved to VI grade 2, then', '1 50 mg/m\u00b2', '1 50 mg/m\u00b2', 'Neutropenic Fever', 'Omit dose level until resolved, then I 50 mg/m\u00b2', '1 50 mg/m\u00b2', 'Other Hematologic', 'Dose modifications for leucopenia, thrombocytopenia, and anemia during a cycle of', 'Toxicities', 'therapy and at the start of subsequent cycles of therapy are also based on NCI toxicity', 'criteria and are the same as those recommended for neutropenia above', 'Diarrhea', '1 (2 - 3 stools/day)', 'Maintain dose level', 'Maintain dose level', '2 (4 - 6 stools/day)', '1 25 mg/m\u00b2', 'Maintain dose level', '3 (7 - 9 stools/day)', 'Omit dose level unit resolved to VI grade 2, then', '1 25 mg/m\u00b2', '1 25 mg/m\u00b2', 'Omit dose level until resolved to grade 2, then', '4 (10 stools/day)', '1 50 mg/m\u00b2', '1 50 mg/m\u00b2', 'Other nonhematologic', 'toxicitiesd', '1', 'Maintain dose level', 'Maintain dose level', '2', '1 25 mg/m\u00b2', 'Maintain dose level', '3', 'Omit dose level until resolved to grade 2, then', '1 25 mg/m\u00b2', '1 25 mg/m\u00b2', '4', 'Omit dose level until resolved to VI grade 2, then', '1 50 mg/m\u00b2', '1 50 mg/m\u00b2', 'a All dose modifications should be made based on the worst preceding toxicity.', 'b', 'National Cancer Institute Common Toxicity Criteria (version 4.0)', 'c All numbers refer to increase over number of pre-treatment number of stools/day', 'd', 'Excludes anorexia, alopecia, fatigue, asthenia, and laboratory abnormalities that are not felt to be clinically', 'significant', 'Regeneron Pharmaceuticals, Inc.', 'Page 79 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1. Approved - 14 Apr 2021 GMT-5:00']['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', '8.4.4.', 'Gemcitabine Dose Modifications', 'The dose reduction guidelines for myelosuppression on days 1 and 8 (of a 3-week - treatment course', 'of gemcitabine) are in Table 11.', 'Table 11:', 'Dose Modifications for Gemcitabine for Myelosuppression on Day of', 'Treatment', 'Treatment Day', 'Absolute Neutrophil', 'Platelet Count', '% of Full Dose', 'Count', '(X 106/L', '(X 106/L', 'Day 1', '>1500', 'And', '> 100 000', '100%', '<1500', 'Or', '< 100 000', 'Hold', 'Day 8', '>1500', 'And', '>100 000', '100%', '1000-1499', 'Or', '75000-99999', '50%', '<1000', 'Or', '<75000', 'Hold', 'The dose reduction guidelines for myelosuppression (of a 3-week treatment course of gemcitabine)', 'on in the preceding cycle are in Table 12.', 'Table 12:', 'Gemcitabine Dose Modifications for Myelosuppression in Preceding Cycle', 'Occurrence', 'Myelosuppression During Treatment Cycle', 'Dose Modification', 'Initial', 'ANC <500 X 106/L for more than 5 days', 'Permanently reduce gemcitabine', 'Occurrence', 'ANC <100 X 106/L for more than 3 days', 'to 800 mg/m\u00b2 on days 1 and 8', 'Febrile Neutropenia', 'Platelets <25000 X 106/L', 'Cycle delay > 1 week due to toxicity', 'Subsequent', 'If any of the above toxicities occurred after the', 'Permanently reduce gemcitabine', 'Occurrence', 'initial dose reduction', 'to 800 mg/m\u00b2 on day 1 only', 'Permanently discontinue gemcitabine for any of the following:', 'Unexplained dyspnea or other evidence of severe pulmonary toxicity', 'Severe hepatic toxicity', 'Hemolytic-Uremic Syndrome', 'Capillary Leak Syndrome', 'Posterior reversible encephalopathy syndrome', 'Withhold gemcitabine or reduce dose by 50% for other severe (grade 3 or 4) nonhematologic', 'toxicity until resolved. No dose modifications are recommended for alopecia, nausea, or vomiting.', 'Regeneron Pharmaceuticals, Inc.', 'Page 80 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.0 Approved - 14 Apr 2021 GMT-5:00']\n\n###\n\n", "completion": "END"}